๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Treatment of MOPP-refractory Hodgkin-s disease with vinblastine, doxorubicin, bleomycin, CCNU, and dacarbazine

โœ Scribed by Lawrence H. Einhorn; Stephen D. Williams; Eugene E. Stevens; William H. Bond; Linda Chenoweth

Publisher
John Wiley and Sons
Year
1983
Tongue
English
Weight
419 KB
Volume
51
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

โœฆ Synopsis

Eighteen patients with advanced Hodgkin's disease, refractory to combination chemotherapy with nitrogen mustard, vincristine, prednisone, and procarbazine (MOPP), were treated with vinblastine, doxorubicin (Adriamycin), bleomycin, CCNU, and dacarbazine (DTIC) (VABCD). Fifteen patients had Stage IV disease and 11 had systemic symptoms. Although hematologic toxicity was considerable, there was no drug related mortality. Eight patients achieved a complete remission (CR), and five are currently in a continuous CR of five, 24, 30, 34, and 36 months duration, respectively. An additional patient had a 30-month CR and relapsed with localized lymphadenopathy and is currently disease-free following involved-field radiotherapy 46 months from initiation of VABCD. This study suggests that long-term disease-free survival and potential cure can be achieved with VABCD in MOPP-refractory Hodgkin's disease.

๐Ÿ“œ SIMILAR VOLUMES

ACUTE MYELOID LEUKEMIA FOLLOWING THERAPY
ACUTE MYELOID LEUKEMIA FOLLOWING THERAPY OF HODGKIN'S DISEASE WITH RADIOTHERAPY AND ABVD (DOXORUBICIN, BLEOMYCIN, VINBLASTINE, AND DACARBAZINE)
โœ J. H. LIPTON; M. GOSPODAROWICZ; S. REINGOLD ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 185 KB ๐Ÿ‘ 1 views

A 26-year-old man developed myelodysplasia rapidly progressing to acute myelomonocytic leukemia 3 years after receiving three cycles of ABVD chemotherapy and upper mantle and upper abdomen radiotherapy for stage IA Hodgkin's disease. This represents the fourth such case reported. The risk of seconda

Treatment of advanced Hodgkin's disease
Treatment of advanced Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide (ABVD) after failure of MOPP therapy
โœ John G. Krikorian; Carol S. Portlock; Dr. Saul A. Rosenberg ๐Ÿ“‚ Article ๐Ÿ“… 1978 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 359 KB ๐Ÿ‘ 2 views

twenty-seven patients with advanced Hodgkin's disease who failed MOPP (nitrogen mustard, vincristine, procarbazine and prednisone) were treated with adriamycin, bleomycin, vinblastine, and imidazole carboxamide, (ABVD). Complete response (CR) was achieved in 22% of patients and partial response was

Treatment of Hodgkin's disease in childr
Treatment of Hodgkin's disease in children with alternating mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) and adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) courses without radiotherapy
โœ van den Berg, Henk; Stuve, Wouter; Behrendt, Henk ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 108 KB ๐Ÿ‘ 1 views

Since the introduction of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) chemotherapy, children with Hodgkin's disease (HD) have been treated with chemotherapy alone. The occurrence of side effects related to irradiation (especially secondary solid tumors) is less likely to occur.

Hybrid chemotherapy consisting of cyclop
Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced hodgkin disease
โœ Silvia Montoto; Mireia Camรณs; Armando Lรณpez-Guillermo; Francesc Bosch; Francisco ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 91 KB

## BACKGROUND. Combination chemotherapy, including hybrid regimens, is the standard treatment for patients with advanced Hodgkin disease (HD). Although a prolonged complete response (CR) is achieved in up to 70 -80% of patients, long term complications, such as secondary leukemia, are of concern. C